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Abstract
Influenza A (H5N1) viruses continue to pose a public health threat. As inactivated H5N1 vaccines 
are poorly immunogenic, adjuvants are needed to improve the immunogenicity of H5N1 vaccine 
in humans. Here, we investigated the immunogenicity and cross-protective efficacy in ferrets of a 
clade 2.2-derived vaccine with addition of JVRS-100, an adjuvant consisting of cationic liposome–
DNA complexes (CLDC). After the first vaccination, significantly higher levels of 
hemagglutination-inhibition (HAI) and neutralizing antibody titers were detected in ferrets 
immunized with adjuvanted vaccine compared to unadjuvanted vaccine. Following a second dose 
of adjuvanted vaccine, HAI antibody titers of ≥40 were detected against viruses from multiple 
H5N1 clades. HAI antibodies against newly isolated H5N2 and H5N8 viruses were also 
augmented by JVRS-100. Ferrets were challenged with a heterologous H5N1 virus. All ferrets that 
received two doses of adjuvanted vaccine exhibited mild illness, significantly reduced nasal wash 
virus titers and protection from lethal challenge. In contrast, ferrets that received unadjuvanted 
vaccine showed greater weight loss, high viral titers and 3 of 6 animals succumbed to the lethal 
challenge. Our results indicate that the addition of JVRS-100 to H5N1 vaccine enhanced 
immunogenicity and cross-protection against lethal H5N1 virus disease in ferrets. JVRS-100 
warrants further investigation as a potential adjuvant for influenza vaccines.
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1. Introduction
Influenza is an acute respiratory disease caused by infection with influenza viruses (Centers 
for Disease Control and Prevention, 2010). Seasonal influenza viruses that circulate annually 
in humans including influenza A (H3N2 and H1N1 subtypes) and B viruses result in more 
than 200,000 respiratory and circulatory hospitalizations each year, and an average of 23,000 
annual influenza-associated deaths in the United States (Centers for Disease Control and 
Prevention, 2010; Thompson et al., 2004). With the implementation of influenza vaccination 
programs, illness and hospitalizations associated with seasonal influenza virus have been 
substantially averted in the United States (Kostova et al., 2013). However, there are far fewer 
licensed pre-pandemic vaccines available for use against other influenza A subtypes such as 
avian influenza A (H5N1) virus that has caused sporadic human infections since 1997 
(WHO, 2014) and A (H7N9) that have caused outbreaks of human illness in China since 
February 2013 (Gao et al., 2013). The continuing occurrence of avian influenza virus 
infections in humans and the suboptimal immunogenicity of vaccines that target them, 
highlight the need for the development of improved vaccines strategies (Bart et al., 2014; 
Prieto-Lara and Llanos-Mendez, 2010; Treanor et al., 2006).
Highly pathogenic avian influenza (HPAI) A (H5N1) virus was first isolated from humans in 
Hong Kong in 1997 (Subbarao et al., 1998), and continues to cause outbreaks in poultry and 
sporadic human infections (WHO, 2012). Continued evolution of HPAI H5 virus has led to 
the emergence of 40 phylogenetically distinct HA clades of the virus (Smith et al., 2015). 
Viruses from clades 0, 1, 2, and 7 have caused human disease (Writing Committee of the 
Second World Health Organization Consultation on Clinical Aspects of Human Infection 
with Avian Influenza A (H5N1) Virus et al., 2008), but clade 1 and clade 2 viruses are 
responsible for recent human infections (WHO, 2015b). Between 2003 and November 2015, 
the World Health Organization (WHO) reported 844 laboratory confirmed human cases of 
H5N1 virus infection with a case fatality rate of approximately 53% (WHO, 2015a). Recent 
studies suggest that H5N1 virus have the potential to acquire airborne transmission in 
mammals (Herfst et al., 2012; Imai et al., 2012). Furthermore, humans are largely 
serologically naive to the H5N1 subtype based on the available H5N1 seroepidemiologic 
studies (Liao et al., 2013; Nasreen et al., 2013; Van Kerkhove, 2013). In addition, newly 
isolated HPAI H5 viruses have recently caused outbreaks in wild birds and domestic poultry 
in Asia, Europe, and North America (Jhung et al., 2015; Smith et al., 2015; WHO, 2015b). 
Although human infections caused by these viruses have not been detected to date, their 
appearance in North America highlights the intercontinental spread of H5 virus, the genetic 
reassortment with regionally circulating avian influenza viruses, and collectively, represents 
a significant threat to human health (Smith et al., 2015).
As vaccination is one of the most effective strategies for prevention and control of seasonal 
and pandemic influenza, H5 vaccines have been developed and evaluated intensively in both 
preclinical studies in mice or ferrets, and in humans (Baras et al., 2008a, 2008b; Baz et al., 
2013; Belshe et al., 2014; Leroux-Roels and Leroux-Roels, 2009; Subbarao and Luke, 
2007). In preclinical and clinical trials, inactivated H5N1 vaccines were consistently poorly 
immunogenic when administered to animals or human volunteers without adjuvant. The 
addition of proprietary oil-in-water emulsion adjuvants such as AS03 and MF59 to 
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inactivated H5N1 vaccines has enhanced vaccine immunogenicity and cross-clade reactivity 
(Baras et al., 2008a, 2008b; Belshe et al., 2014; Bihari et al., 2012), but predominantly 
stimulate humoral immune responses; the role of cellular immune responses in post-
vaccination protection has not been clearly elucidated (Leroux-Roels, 2009; Radosevic et al., 
2008; Valensi et al., 1994). Previous murine studies showed that squalene-based MF59 
adjuvant primarily enhances the Th2/IgG1 response to inactivated influenza vaccine and has 
little effect on the Th1/IgG2a response that is superior in providing protection against 
infections from antigenically drifted or shifted influenza viruses in mice (Moran et al., 1999; 
Valensi et al., 1994). Given the rapid antigenic evolution of H5 virus, the use of an adjuvant 
promoting Th1 response result in both humoral and cell-mediated immune responses that 
may lead to better cross-protection against heterologous H5 virus infection (Thomas et al., 
2006).
JVRS-100 is comprised of cationic liposome–DNA complexes (CLDC) and was developed 
as an adjuvant for vaccines against infectious diseases and as an immunomodulator for 
cancer therapy (Bernstein et al., 2009; Chang et al., 2009; Lay et al., 2009; Zaks et al., 
2006). It has been demonstrated that the addition of CLDC to influenza vaccines can induce 
robust CD4+ Th1 response and predominant IgG2a/c antibody responses in mice (Chang et 
al., 2009; Dong et al., 2012; Hong et al., 2010; Lay et al., 2009). Most noteworthy, enhanced 
multicytokine-producing influenza virus-specific CD4+ and CD8+ T-cell responses were 
demonstrated in mice and non-human primates, and enhanced cross-protection were 
demonstrated in mice with addition of CLDC to influenza vaccines (Hong et al., 2010; Lay 
et al., 2009). In a previous study, we demonstrated that a JVRS-100 adjuvanted clade 1 
H5N1 split vaccine showed significantly improved immunogenicity and antigen-sparing 
effect, stimulated enhanced cross-clade antibody and CD4+ T-cell responses, and provided 
significant cross-clade protection in mice (Dong et al., 2012). Ferrets have been widely used 
and recognized as the most suitable pre-clinical challenge model to evaluate the 
immunogenicity and protective efficacy of influenza vaccines (Baras et al., 2008b; Subbarao 
and Luke, 2007; Zitzow et al., 2002). Therefore, pre-clinical data generated in this species 
could be predicative of clinical trials in humans when it is not possible to conduct 
experimental challenge of HPAI H5 virus in human volunteers (Subbarao and Luke, 2007). 
Here, we investigated the immunogenicity of a JVRS-100 adjuvanted clade 2.2 H5N1 split 
vaccine from the US pre-pandemic influenza vaccine stockpile, and evaluated the cross-
protective efficacy against infection with a heterologous H5N1 strain in ferrets.
2. Materials and methods
2.1. Viruses
HPAI H5N1 viruses used in this study included A/bar-headed goose/Qinghai/1A/2005 (BH/
05), A/Indonesia/05/2005 (IN/05), A/Hong Kong/156/1997, A/Vietnam/1203/2004, A/
Cambodia/X012331/2013, A/Indonesia/NIHRD/12379/2012, A/Bangladesh/3233/2011, A/
Anhui/1/2005, and A/Hong Kong/6841/2010. HPAI H5N8 (A/gyrfalcon/Washington/
410886/2014) and H5N2 (A/northern pintail/Washington/40964/2014) viruses were also 
used. Virus stocks were propagated in the allantoic cavity of 10 day-old embryonated 
chicken eggs, then were aliquoted and stored at −80 °C until used. Fifty percent egg-
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infectious dose (EID50) titers were determined by serial titration of virus in eggs (Lu et al., 
1999). Virus propagation and titration were conducted under biosafety level 3 containment 
with enhancements (BSL-3E) required by the U.S. Department of Agriculture and the Select 
Agent Program to ensure the safety of laboratory workers, the environment, and the public 
(http://www.cdc.gov/biosafety/publications/bmbl5/).
2.2. Preparation of JVRS-100 adjuvanted H5N1 vaccine
JVRS-100 (Colby Pharmaceuticals, San Jose, CA) was manufactured from pDNA 
(pMB75.6) with DOTIM/cholesterol liposomes as previously described (Lay et al., 2009). 
Inactivated split egg-based BH/05 clade 2.2 H5N1 vaccine (Lot no. UD10026) was 
manufactured by Sanofi Pasteur and obtained through the Department of Health and Human 
Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical 
Advanced Research and Development Authority (BARDA). Vaccine potency was 
established by the Center for Biologics Evaluation and Research, Food and Drug 
Administration (CBER/FDA). The vaccine was diluted in 5% dextrose in water and then 
mixed with JVRS-100 prior to immunization.
2.3. Immunization of ferrets
Male Fitch ferrets, 6–8 months of age (Triple F Farms, Sayre, PA), were housed in cages 
within a Duo-Flo Bioclean mobile clean room (Lab Products, Seaford, DE) throughout the 
experiment. Ferrets were confirmed to be serologically negative by HAI assay for currently 
circulating seasonal influenza viruses. Baseline serum, temperature and weight 
measurements were obtained prior to challenge as previously described (Maines et al., 
2005). Ferrets were anesthetized with an intramuscular (i.m.) injection of ketamine 
hydrochloride cocktail [ketamine, xylazine, and atropine]. Groups of 6 ferrets received 
intramuscularly 2 doses 28 days apart of one of the following: (1) JVRS-100 adjuvanted 
BH/05 vaccine containing 7.5 μg HA+15 μg of JVRS-100/per dose; (2) BH/05 vaccine alone 
(7.5 μg HA/per dose); and (3) JVRS-100 only (15 μg/per dose). The animals were injected 
i.m. with 250 μl of vaccine into the right hind leg muscle. Serum samples were collected on 
day 0 and 28 after the first immunization, 2 weeks and 2 months (pre-challenge) after the 
second immunization then frozen at −20 °C until testing.
2.4. Serological assays
Serum samples were treated with receptor-destroying enzyme from Vibrio cholerae (Denka-
Seiken, Tokyo, Japan) before testing for the presence of virus-specific antibodies. The HAI 
assay was performed using 4 hemagglutination units (HAU) of live H5N1 virus and 1% 
horse red blood cells (Stephenson et al., 2004). Titers of neutralizing antibody were 
determined by microneutralization (MN) assay as previously described (WHO, 2011). Both 
HAI and MN assays were performed under BSL-3E containment.
2.5. Ferret challenge with H5N1 virus
Ferrets were challenged 2 months after the second immunization with a lethal dose (106 
EID50) of IN/05 H5N1 virus administered intranasally (i.n.) and then monitored daily for 
clinical signs of infection, weight loss, and survival. Nasal washes were collected at day 2, 4, 
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and 6 post-infection (p.i.), and were titrated in eggs as previously described (Maines et al., 
2005). Ferrets that lost more than 25% of total body weight or exhibited signs of 
neurological dysfunction were euthanatized. All animals used in this study were cared for in 
accordance with the guidelines of the Committee on Care and Use of Laboratory Animals 
(Institute of Laboratory Animal Resources, National Research Council) under an animal use 
protocol approved by CDC’s Institutional Animal Care and Use Committee. The challenge 
experiment was conducted under animal BSL-3E containment.
2.6. Statistical analysis
Data were analyzed using GraphPad Prism 5 software (Graph-Pad Software, Inc., San 
Diego, CA). Statistical significance of the data was determined by using t test, or Kaplan-
Meier survival curves and log rank tests to calculate p values. p < 0.05 was considered as a 
significant difference.
3. Results
3.1. Immunogenicity of JVRS-100 adjuvanted clade 2.2 H5N1 split vaccine in ferrets
To evaluate whether JVRS-100 could enhance immunogenicity of an H5N1 vaccine, ferret 
sera were collected four weeks after the first immunization and two weeks after the second 
immunization. As shown in Fig. 1, ferrets that received JVRS-100 only did not exhibit any 
HAI or MN antibodies at any time point. Vaccine administered without adjuvant elicited 
little or no detectable serum HAI and MN antibodies even after two doses. In contrast, the 
administration of one dose of BH/05 vaccine with JVRS-100 resulted in a significantly 
higher response in HAI antibody titers compared to the vaccine alone group (p<0.01); 50% 
(3/6) of the ferrets exhibited an HAI titer of 40, which is generally accepted to represent a 
50% protective titer for seasonal influenza A (H3N2) viruses in adult populations (Potter 
and Oxford, 1979). Following the second immunization of adjuvanted vaccine, the serum 
antibody response was further boosted and all the ferrets achieved HAI and MN titers of≥80 
to the homologous virus. These results demonstrate that the JVRS-100 adjuvant significantly 
enhanced the immunogenicity of the clade 2.2 split vaccine in ferrets.
3.2. Cross-reactive HAI antibody responses of JVRS-100 adjuvanted clade 2.2 H5N1 split 
vaccine
To investigate whether the administration of JVRS-100 adjuvant to a clade 2.2 vaccine could 
also augment cross-clade antibody responses, sera from each group of six ferrets collected 
two weeks after the second immunization were evaluated by HAI assays against 11 H5 
viruses isolated between 1997 and 2014 (Table 1). BH/05 vaccine alone failed to induce 
detectable amounts of HAI antibody to the homologous and heterologous H5 viruses. In 
contrast, JVRS-100 adjuvanted BH/05 vaccine not only significantly enhanced cross-
reactive HAI antibody response to the 1997–2013 H5N1 viruses (p<0.01), but also 
significantly enhanced cross-reactive HAI antibody response against heterologous 2014 
H5N2 and H5N8 viruses (p<0.01) compared to the vaccine only group. Collectively, our 
results demonstrated that co-administration of JVRS-100 with a clade 2.2 H5N1 split 
vaccine in ferrets can enhance HAI antibody responses to the homologous and heterologous 
H5 viruses isolated between 1997 and 2014.
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3.3. Cross-protective efficacy of JVRS-100 adjuvanted clade 2.2 H5N1 split vaccine in 
ferrets
Ferret sera were collected before challenge (2 months after the second immunization) and 
tested for HAI and MN antibodies to BH/05 and IN/05 viruses. As presented in Table 2, no 
pre-challenge HAI and MN antibodies were detected in ferrets immunized with vaccine 
alone. In contrast, ferrets that received vaccine with JVRS-100 exhibited substantial 
antibody titers to BH/05 and IN/05 viruses with HAI and MN GMTs of > 40 (p<0.01).
Protective efficacy against heterologous IN/05 virus was augmented by JVRS-100. As 
presented in Table 2, ferrets that received vaccine alone or JVRS-100 alone showed 
significantly higher virus titers in nasal washes on day 2, 4 and 6 p.i. compared to ferrets that 
received adjuvanted vaccine (p<0.01). The formulation of vaccine with JVRS-100 resulted 
in about an 80-fold and 300-fold reduction of viral titer respectively on day 2 and 4 p.i. 
compared to the vaccine alone group, and complete clearance of virus in nasal washes on 
day 6 p.i. In accordance with the significantly reduced virus titers in nasal washes, all ferrets 
that received JVRS-100 adjuvanted vaccine survived a lethal challenge with a very high dose 
of the heterologous virus and exhibited significantly reduced morbidity as reflected by a 
reduction of weight loss compared to ferrets that received vaccine alone or adjuvant alone 
(p<0.01, Fig. 2). In contrast, all ferrets that received JVRS-100 alone, and 3 of 6 ferrets that 
received vaccine alone, died 5–7 days p.i., These results indicate that the addition of 
JVRS-100 to H5N1 vaccine increased the level of cross protective immunity against a 
heterologous HPAI H5N1 virus challenge.
4. Discussion
HPAI clade 2.2 H5N1 viruses were first detected in migratory birds in central China in 2005, 
and were associated with mass die-offs of wild-birds (WHO, 2012). Since 2005, the 
numbers of affected countries and confirmed cases of H5N1 virus infection have increased, 
in part because of the spread of clade 2.2 viruses across Eurasia and to Africa (Writing 
Committee of the Second World Health Organization Consultation on Clinical Aspects of 
Human Infection with Avian Influenza A (H5N1) Virus et al., 2008; WHO, 2012, 2015a). In 
this study, we have shown that the addition of JVRS-100 to BH/05 clade 2.2-derived H5N1 
vaccine, a component of the current US pre-pandemic influenza vaccine stockpile, resulted 
in significant enhancement of serum HAI and MN antibody responses in ferrets after the 
first and second vaccinations compared with unadjuvanted vaccine, and provided significant 
cross-protection from a lethal challenge with a highly virulent heterologous clade 2.1.3.2 
virus, which has caused 199 human infections in Indonesia with very high fatality rate 
(84%) (WHO, 2015a). Furthermore, JVRS-100 addition also improved cross-reactive HAI 
antibody responses to clade 0, clade 1, clade 1.1.2, clade 2.1.3.2, clade 2.1.3.2a, clade 2.2.2, 
clade 2.3.4, and clade 2.3.2.1c H5N1 viruses isolated between 1997 and 2013, as well as 
clade 2.3.4.4 H5N2 and H5N8 viruses that emerged in late 2014. These data are consistent 
with our previous study showing that the addition of JVRS-100 to a licensed clade 1 H5N1 
vaccine significantly enhanced cross-reactive antibody responses to clade 2.2.1 and clade 
2.3.4 H5N1 viruses and provided significant cross-protections to lethal challenges with these 
viruses in mice (Dong et al., 2012). Importantly, JVRS-100 addition also resulted in 
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significant cross-clade Th1 CD4+ T-cell responses and dose-sparing in mice (Dong et al., 
2012). The ability conferred by an adjuvant to elicit broad cross-clade protective immunity 
and antigen-sparing would be highly advantageous in the early stages of a pandemic to 
provide herd immunity in human populations, since it will take months for the current 
manufactures to produce well-matched vaccine with sufficient doses supply.
The addition of JVRS-100 to commercially available 2006–2007 trivalent inactivated 
seasonal influenza vaccine (TIV) also significantly enhanced HAI antibody responses in 
mice and macaques (Lay et al., 2009), and resulted in significant cross-protection in mice 
from antigenically distinct influenza H1N1, H3N2, and influenza B virus that were isolated 
from humans more than 35 years ago (Lay et al., 2009). Furthermore, JVRS-100 adjuvanted 
inactivated influenza H1N1 vaccine provided significant cross-protection from 
heterosubtypic H3N2 challenges in mice (Hong et al., 2010). Both cellular and antibody-
mediated immunity likely played a role in such cross-protection from antigenically distinct 
influenza viruses (Hong et al., 2010; Lay et al., 2009). Occasionally, seasonal influenza 
vaccine antigens are antigenically drifted from circulating viruses which may in some cases 
lead to lower vaccine effectiveness (Flannery et al., 2015; Klimov et al., 1999; McNeil et al., 
2015). The addition of adjuvants such as JVRS-100 to antigenically mismatched inactivated 
seasonal influenza vaccine might improve immune responses and broaden immune 
protection when a well-matched vaccine could not be prepared in time (Lay et al., 2009; 
Moran et al., 1999).
CLDC formed adjuvants such as JVRS-100 were particularly effective in eliciting strong T 
cell responses, even at low antigen doses (Hong et al., 2010; Lay et al., 2009; Zaks et al., 
2006). The CD4+ and CD8+ T cells elicited by JVRS-100 adjuvanted influenza vaccine 
secrete multiple cytokines with a poly-functional phenotype in non-human primates (Lay et 
al., 2009). JVRS-100 adjuvanted vaccine also induced influenza virus-specific cytotoxic 
CD8+ T cells directed to the internal viral protein epitopes common to heterologous 
influenza strains (Hong et al., 2010; Thomas et al., 2006). Importantly, this superior cross-
reactive CD8+ T cell reactivity induced by CLDC adjuvant persisted for long periods of time 
in mice lung tissues (Zaks et al., 2006), and was associated with significantly reduced 
morbidity and mortality in mice after heterosubtypic influenza viral challenges (Hong et al., 
2010). Furthermore, increasing evidences showed that strong T cell responses to more 
conserved influenza internal viral proteins were associated with reduced disease severity in 
humans (Li et al., 2013; Sridhar et al., 2013; Wilkinson et al., 2012). Thus, influenza 
vaccines that can significantly boost heterosubtypic CD4+ and CD8+ T-cell responses, in 
addition to inducing neutralizing antibodies to the circulating viruses, may offer broader 
protection against drifted epidemic viruses and possibly even pandemic viruses. (Li et al., 
2013; Sridhar et al., 2013; Wilkinson et al., 2012). Unfortunately, we cannot rule out a role 
of T cell-mediated immunity in cross-protection in this ferret model. However, it is plausible 
that the reduced amount of virus shedding and faster clearance of virus in ferrets might, in 
part, be due to a robust T cell immune response stimulated by JVRS-100 adjuvanted vaccine 
(Hong et al., 2010; Moran et al., 1999).
Our previous study indicated that immunization with JVRS-100 adjuvanted H5N1 vaccine 
induced long-lasting HAI antibody responses in mice (Dong et al., 2012). It is intriguing to 
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note that HAI antibody titers induced by the two doses of JVRS-100 adjuvanted H5N1 
vaccine in ferrets declined 2–4 fold at 2 months compared to the time period of 2 weeks 
after the second immunization. The decay of the HAI antibody response was also observed 
in ferrets, but not in mice following immunization with alum adjuvanted H5 vaccines 
(Layton et al., 2011; Lu et al., 1999). The decay of the HAI antibody response was also 
observed in adults immunized with oil-in-water adjuvanted H5 vaccines (Leroux-Roels et 
al., 2010). Although antibody titers decreased with time, oil-in-water adjuvanted H5 vaccine 
can elicit long-term memory B cells in humans (Khurana et al., 2014) and alum adjuvanted 
H5 vaccine can induce long-term protection against HPAI H5N1 infection in ferrets (Layton 
et al., 2011). Nevertheless, successful vaccination regimes rely on the generation of long 
lived plasma cells and long-lived memory B cells (Tarlinton and Good-Jacobson, 2013). 
Investigation of immune memory enhanced by different adjuvants, including JVRS-100, 
may reveal mechanisms underlying the different half-lives of humoral immunity in different 
species. This may also lead to the development of better adjuvants that could enhance long-
lasting protective immunity in humans, which is an area requiring more research.
Our data, together with other previous findings indicate that the addition of JVRS-100 
adjuvant to influenza vaccines induces CD4+ Th1 biased immune response, cross-reactive 
antibody responses, functional memory CD8+ T-cell responses, and broad cross-protection 
in multiple species (Dong et al., 2012; Hong et al., 2010; Lay et al., 2009). Novel adjuvants 
such as JVRS-100 that can stimulate multiple immune pathways to enhance immunogenicity 
and protective efficacy warrant further investigation as potential adjuvants for inactivated 
vaccines against H5N1 and other influenza viruses with pandemic potential.
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Fig. 1. 
Serum HAI and MN antibody responses of ferrets immunized with BH/05 split vaccine with 
or without JVRS-100. Ferrets were immunized i.m with one or two doses of JVRS-100 
alone (15 μg/ferret), vaccine alone (7.5 μg HA/ferret), or vaccine with JVRS-100 (7.5 μg HA
+15 μg JVRS-100/ferret). Sera were collected 4 weeks after the first dose (black dots) and 2 
weeks after the second dose (open dots), and then tested individually for HAI (A) and MN 
(B) antibodies against the homologous virus. Antibody titers are expressed as the reciprocal 
of the highest serum dilution inhibiting agglutination of 1% horse erythrocytes by 4 HAU of 
virus, or neutralizing 100 TCID50 amount of virus. Solid bars represent geometric mean 
titers (GMTs) of 6 ferrets per group. Dashed lines indicate the HAI and MN titer of 40. A 
responder is defined by neutralizing antibody titers≥20. *p<0.01 compared to BH/05 vaccine 
alone group.
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Fig. 2. 
JVRS-100 adjuvanted clade 2.2 H5N1 vaccine significantly improves survival and morbidity 
against a heterologous clade 2.1.3.2 H5N1 virus infection. Groups of 6 ferrets were 
immunized i.m. with two doses of JVRS-100 alone (15 μg/ferret), vaccine alone (7.5 μg HA/
ferret), or vaccine with JVRS-100 (7.5 μg HA+15 μg JVRS-100/ferret). Two months after 
the second dose, ferrets were challenged i.n. with 106 EID50 of the heterologous IN/05 
H5N1 virus. Ferrets were monitored daily for weight loss and survival for 14 days. *p<0.01 
compared to BH/05 vaccine alone group.
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